📰 Tender Offer Statement News
Page 2 - Tender Offer Statement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tender Offer Statement. Real-time updates on events, politics, business and more.
April 11, 2024
EQS-News: MorphoSys AG / Key word(s): Mergers & Acquisitions/Disposal MorphoSys’ Management Board and Supervisory ...
April 11, 2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire ...
April 11, 2024
MorphoSys Management Board and Supervisory Board Recommend Shareholders ...
April 1, 2024
SHANGHAI, April 01, 2024 -- H World Group Limited , a key player in the global hotel industry, today announced that it is notifying holders of its 3.00% Convertible Senior Notes due 2026 that...
March 26, 2024
/PRNewswire/ -- Sphinx Investment Corp. ("Sphinx") today announced that it has extended the expiration date of its previously announced offer to purchase all...
March 13, 2024
EQS-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01...
February 20, 2024
Renesas Electronics Corporation and Sequans Communications S.A. today announced that Renesas has extended the expiration date of its tender offer to acquire all of the outstanding ordinary shares...
February 15, 2024
Diversified Energy Company announces the opportunity for shareholders to choose how they receive a US$42 million return of capital.
February 15, 2024
CALGARY, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“
February 13, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the ...